On March 20, 2026, CMS finalized a landmark rule phasing out fax machines and postal mail for healthcare claims documentation, adopting national electronic standards for claims attachments. The rule projects $781.98 million in annual savings for the healthcare industry and applies to all HIPAA-covered entities — health plans, clearinghouses, and providers conducting electronic transactions.
| Metric | Value |
|---|---|
| Projected annual savings | $781.98 million |
| Effective date | May 26, 2026 |
| Compliance deadline | May 26, 2028 |
| Applies to | All HIPAA-covered entities |
Simultaneously, the OPPS Drug Acquisition Cost Survey (ODACS) deadline was extended from March 31 to April 7, 2026. The MedPAC March 2026 Report recommended a net physician payment reduction of 1.2%–1.7% for FY 2027 after the temporary 2.5% statutory bump expires at end of 2026.
The current 2.5% statutory payment bump expires December 31, 2026. MedPAC’s FY 2027 recommendations signal a net payment reduction for physicians unless Congress acts. Practices should model 2027 scenarios now — not after the cliff arrives.
The March 31, 2026 deadline under CMS’s Interoperability and Prior Authorization Final Rule (CMS-0057-F) marks a watershed moment: for the first time, impacted payers must publicly report prior authorization metrics for Calendar Year 2025. This includes approval/denial percentages, appeal overturn rates, average decision turnaround times, and requests for additional information — broken down by contract, state, or plan level.
| Metric Required | Detail |
|---|---|
| % of PA requests approved/denied | By plan/contract level |
| % approved after appeal | Overturn transparency |
| Average decision turnaround | Submission to decision |
| Additional info requests | Frequency of payer follow-up |
The CAQH Index estimates electronic prior authorization standards save 14 minutes per authorization and $515 million annually in industry-wide administrative costs. Aetna now provides preauthorization bundles for musculoskeletal conditions and cancer imaging. BCBS is targeting 80% near-real-time electronic PA responses by 2027.
After March 31, pull each payer’s published PA metrics and compare against your own internal PA tracking data. Any significant discrepancies between your denial experience and their reported rates should trigger a payer meeting or formal dispute.
HIMSS26 (March 9–12, Las Vegas) marked the moment agentic AI shifted from concept to commercially deployed product across the revenue cycle. Multiple major vendors shipped autonomous AI agents capable of end-to-end claim processing, denial prevention, and appeal generation — with measurable production results.
| Vendor | Key Announcement | Production Result |
|---|---|---|
| Waystar | Google Cloud partnership; AltitudeAI expansion | $15B in prevented denials; 90% faster appeals; ~99% clean claim rate |
| Epic | Agent Factory (no-code AI agent builder) | 85%+ customers using Epic AI; 42% faster PA submission; 20%+ coding denial reduction |
| FinThrive | 50+ AI use cases across Fusion architecture | 1.1% underpayment recovery (~$1M/3 months); 2.5% denial rate reduction |
| XiFin | Empower AI RCM Ecosystem | Agentic workflows for correspondence, OOP estimates, denial prioritization, appeal creation |
| athenahealth | MCP Server + athenaConnect interoperability | Natural language AI access for 170,000 providers (20% of U.S. population) |
Waystar earned the #1 overall ranking in Black Book’s Q1 2026 Agentic and Generative AI RCM Benchmark — scoring 9.75/10 across 18 KPIs in a survey of 49 vendors and 750+ senior healthcare leaders.
The “battle of the bots” is now real — payers use AI to drive more denials while providers deploy AI to fight back. Practices without AI-powered denial prevention are bringing a knife to a gunfight. Waystar’s $15 billion in prevented denials and Epic’s 42% PA time reduction are production numbers, not pilot projections.
The April 1, 2026 HCPCS Level II quarterly update brings 36 new codes, primarily for injectable drugs, biologics, and skin substitute products. Medicare Administrative Contractors have until April 6 to implement changes. Simultaneously, UnitedHealthcare’s aggressive coding enforcement actions are reshaping claim submission requirements across specialties.
| Update | Detail |
|---|---|
| New diagnosis codes | 487 new codes, 38 revisions, 28 deletions |
| BMI codes | Now require an associated reportable diagnosis (e.g., obesity) |
| New code E11.A | Type 2 DM without complications in remission |
| COVID-19 | Updated code pairing requirements for respiratory manifestations |
UHC’s Excludes 1 enforcement is a denial trap for practices that haven’t updated their code validation logic. Run a retroactive audit of all UHC claims submitted since March 1 to identify and correct any mutually exclusive diagnosis code pairings before they become uncollectible.
The RCM performance gap between top performers and the median continues to widen. Initial denial rates hit 11.8% in 2024 (up from 10.2%), with $262 billion in claims denied annually out of $3 trillion submitted. The most alarming statistic: 65% of denied claims are never resubmitted — representing massive, preventable revenue leakage.
| KPI | Target (Top Performers) | Industry Median | Danger Zone |
|---|---|---|---|
| Days in A/R | <30 days | 33–42 days | >55 days |
| Clean Claims Rate | >98% | 90–95% | <85% |
| Initial Denial Rate | <5% | 6–13% | >15% |
| Net Collection Rate | >96% | 90–95% | <88% |
| First-Pass Resolution | >90% | 70–85% | <65% |
With 65% of denied claims never resubmitted, the single highest-ROI revenue cycle investment is systematic denial follow-up. Every denied claim that goes unworked is cash left on the table. Build an automated denial worklist with aging alerts before investing in anything else.
The RCM technology landscape saw two landmark developments this week: CodaMetrix earned the inaugural Best in KLAS for Autonomous Medical Coding, and AI-driven RCM startup Adonis closed a $40 million Series C to scale autonomous claim resolution.
Global healthcare RPA market: $1.4B (2022) projected to $14.18B by 2032 (CAGR 26.1%). Agentic bots now adapt to payer portal layout changes without developer rewrites.
If your practice still relies on 100% manual coding, the KLAS validation of autonomous coding is your signal to evaluate. CodaMetrix, AKASA, and Epic Penny each serve different practice sizes — request demos with your actual claim volume and specialty mix to compare accuracy rates and ROI projections.
April 1, 2026 marks the enforcement start date for CMS’s updated Hospital Price Transparency requirements under the v3.0 schema. Hospitals face penalties of up to $2,007,500 per year for non-compliance — and the new requirements are significantly more detailed than previous versions.
| Hospital Size | Daily Penalty | Annual Maximum |
|---|---|---|
| Minimum | $300/day | $109,500/year |
| Maximum | $5,500/day | $2,007,500/year |
| Calculation | $10/bed/day | Based on licensed bed count |
| Deadline | Action Item |
|---|---|
| March 31, 2026 | Payers: Publish CY 2025 prior auth metrics (CMS-0057-F) |
| April 1, 2026 | Hospital Price Transparency enforcement begins (v3.0) |
| April 1, 2026 | OPPS new codes effective (COVID-19 mAbs, lab analysis, skin substitutes) |
| April 7, 2026 | ODACS drug acquisition cost survey due (extended) |
| May 1–July 31, 2026 | Clinical Lab private payor rate/volume reporting window |
| May 12–15, 2026 | Updated CMS forms (ABN, Important Message, Detailed Notice) must be in use |
| May 26, 2026 | Electronic claims attachments rule effective |
State Medicaid budgets projected to decline by $664–665 billion (2025–2034). An estimated 5.3 million people could lose coverage from new work requirements. Nebraska implementing early (May 1, 2026).
Practices with hospital-based outpatient departments should confirm their MRF files have been updated to v3.0 schema before April 1. The penalty structure is now aggressive enough to make non-compliance a material financial risk — $10/bed/day adds up quickly for mid-size and large facilities.
Independent practices are at a crossroads. While 47% of physicians have consolidated with hospital systems (up from <30% in 2012), a counter-movement is gaining momentum: micro-practices, direct primary care (DPC) models, and tech-enabled MSOs are enabling physicians to maintain independence while competing on RCM efficiency.
| KPI | Where You Should Be | Industry Median | Action If Below Target |
|---|---|---|---|
| Days in A/R | <35 days | 33–42 days | Implement automated claim status checks and denial worklists |
| Net Collection Rate | >96% | 90–95% | Audit underpayments; automate secondary billing |
| Denial Rate | <8% | 6–13% | Deploy AI-powered claim scrubbing; address top 3 denial codes |
| Clean Claims Rate | >97% | 90–95% | Add front-end eligibility verification automation |
| First-Pass Resolution | >85% | 70–85% | Review coding accuracy and modifier compliance |
| AR >120 Days | <10% | 15–25% | Escalate aged claims to dedicated follow-up team |
Independent practices face a technology adoption gap that directly impacts their denial rates. Payer AI review systems now evaluate authorization requests before human reviewers — practices without matching technology face systematically higher denial rates. The most impactful first investment is automated real-time eligibility verification and claim scrubbing.
| Specialty | Key Update | Data Point | Action |
|---|---|---|---|
| Primary Care | New APCM add-on G-codes (G0556, G0557, G0558) for behavioral health integration; E/M codes exempt from 2.5% efficiency adjustment | CF up to +3.77% for APM participants | Update fee schedules; begin billing APCM codes for qualifying patients |
| Cardiology | New complex PCI category replaces 92928 for bifurcation/multi-vessel lesions; 2.5% efficiency adjustment hits procedural wRVUs | Overall reimbursement ~+1% vs. 2025; 418 CPT changes | Update operative note templates for new PCI codes; model procedural volume impact |
| Orthopedics | Joint arthroplasty documentation requirements tightened; site-of-service a direct reimbursement driver | Denial rates above 20% in some settings; 285 procedures removed from IPO list | Update operative note templates to prevent downcoding; review ASC-eligible procedures |
| Oncology | IRA Maximum Fair Prices slashing drug reimbursement: ibrutinib −38%, pomalidomide −60%, palbociclib −50% | Facility settings ~−11% reimbursement; community ~+6% | Model drug margin impact per protocol; shift eligible infusions to community settings |
| Radiology | Screening mammography RVU reduced 1.82%; screening tomosynthesis reduced 2.55% | Overall −2% for diagnostic radiology; permanent remote imaging supervision finalized | Renegotiate global imaging contracts; leverage remote supervision for staffing |
| Neurology | G35 (multiple sclerosis) deleted — replaced by phenotype/activity-specific codes | Overall +1% payment increase; new Category III codes for continuous EEG/AI-supported EEG | Update MS diagnosis workflows immediately; explore AI-assisted diagnostic coding |
| Mental Health | Permanent telehealth parity; audio-only permanently allowed; LMFTs/LMHCs billing at 75% of psychologist rate | Home = originating site (POS 10, non-facility rates); 6-month in-person visit requirement | Update POS codes for home-based telehealth; set in-person visit scheduling triggers |
| Gastroenterology | New CPT 43889 for Endoscopic Sleeve Gastroplasty (replacing C9784); tighter LCD requirements | PE involvement exceeds 30% in GI; efficiency adjustment hits endoscopy wRVUs | Adopt new gastroplasty code; review LCD compliance for screening vs. diagnostic colonoscopy |
The CMS Generics Leveraging Outsized Biologic Expenditures (GLOBE) model starts October 1, 2026 for Part B physician-administered drugs, ending the traditional ASP + 6% formula. Practices administering biologics and biosimilars should model the financial impact before the transition — community oncology and rheumatology practices will feel this most acutely.
The oncology reimbursement overhaul is the biggest specialty-specific disruption this year. With IRA-driven drug price cuts of 38%–60% on key agents and an 11% facility reimbursement reduction, oncology practices that haven’t modeled per-protocol margins risk discovering revenue shortfalls after the fact. Community oncology settings gain a 6% lift — making site-of-service optimization a strategic imperative.